1645P STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Year: 2023
Type: article
Source: Annals of Oncology
Authors: H.J. Mahadevia, U. Majeed, J. Starr, J.C. Jones, D. Ahn, S. Wu, J. Andring, H. El Shawa, J. Xiu, G. Sledge, I. Astsaturov, S. Goel, P.A. Philip, M. Borad, T. Bekaii-Saab, H. Babiker
Institutions: University of Missouri–Kansas City, Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Mayo Clinic Comprehensive Cancer Center (Arizona), Caris Life Sciences (United States), Fox Chase Cancer Center, Rutgers Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Mayo Clinic in Arizona
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4387810764